Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion type Assertion NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_head.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion description "[At higher doses, differences between the TP53-mutated lines were observed with TOV-112D being less sensitive to cisplatin than OV-90 that also harbors a CDNK2A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_provenance.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion evidence source_evidence_literature NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_provenance.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion SIO_000772 15258697 NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_provenance.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion wasDerivedFrom befree-2016 NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_provenance.
- NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_assertion wasGeneratedBy ECO_0000203 NP452431.RAXOu-aSJiQbCsoErs2pAKCrbNkKPSWRkjDp9VK2DpG10130_provenance.